Azure B and a synthetic structural analogue of methylene blue, ethylthioninium chloride, present with antidepressant-like properties

Life Sciences

Volumn 117, Issue 2, 2014, Pages 56-66

  Delport, Anzelle ^a   Harvey, Brian H ^a   Petzer, Anél ^a   Petzer, Jacobus P ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

Author keywords

Antidepressant; Azure B; Forced swim test; Methylene blue; Monoamine oxidase; Reversible inhibition

Indexed keywords

ANTIDEPRESSANT AGENT; AZURE B; ETHYLTHIONINIUM CHLORIDE; IMIPRAMINE; METHYLENE BLUE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE INHIBITOR; SELEGILINE; SODIUM CHLORIDE; UNCLASSIFIED DRUG; ETHYLTHIONINIUM; GIEMSA STAIN;

ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CYTOTOXICITY; DRUG STRUCTURE; ENZYME ACTIVITY; FORCED SWIM TEST; HELA CELL LINE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC50; IMMOBILITY; LIPOPHILICITY; LOCOMOTION; MALE; NONHUMAN; RAT; SYNTHESIS; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; ANIMAL; CELL CULTURE; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DEPRESSION; DOSE RESPONSE; DRUG EFFECTS; GIEMSA STAIN; MOTIVATION; PHARMACOLOGY; SPRAGUE DAWLEY RAT;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; AZURE STAINS; CELL SURVIVAL; CELLS, CULTURED; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; INHIBITORY CONCENTRATION 50; LOCOMOTION; MALE; METHYLENE BLUE; MOLECULAR STRUCTURE; MONOAMINE OXIDASE INHIBITORS; MOTIVATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84908407321     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2014.10.005     Document Type: Article

References (65)

1. C. Aeschlimann, T. Cerny, and A. Küpfer Inhibition of monoamine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue Drug Metab Dispos 24 1996 1336 1339
2. M. Alda, G. MacQueen, M. McKinnon, J. Granham, S. Maclellan, and T. Hajek P.2.e.001. Methylene blue for residual symptoms and for cognitive dysfunction in bipolar disorder: results of a double-blind trial Eur. Neuropsychopharmacol. 21 Suppl. 3 2011 S417 S418
3. American Psychiatric Association Diagnostic and statistical manual of mental disorders (DSM-IV) 4th ed. 1994 American Psychiatric Association Washington
4. H. Atamna, and R. Kumar Protective role of methylene blue in Alzheimer's disease via mitochondria and cytochrome c oxidase J Alzheimers Dis 20 Suppl. 2 2010 439 452
5. U. Bonnet Moclobemide: therapeutic use and clinical studies CNS Drug Rev 9 2003 97 140
6. C.B. Brink, J.D. Clapton, B.E. Eagar, and B.H. Harvey Appearance of antidepressant-like effect by sildenafil in rats after central muscarinic receptor blockade: evidence from behavioural and neuro-receptor studies J Neural Transm 115 2008 117 125
7. C. Brown, G. Taniguchi, and K. Yip The monoamine oxidase inhibitor-tyramine interaction J Clin Pharmacol 29 1989 529 532
8. J.F. Cryan, A. Markou, and I. Lucki Assessing antidepressant activity in rodents: recent developments and future needs Trends Pharmacol Sci 23 2002 238 245
9. C. D'Sa, and R.S. Duman Antidepressants and neuroplasticity Bipolar Disord 4 2002 183 194
10. A. Dhir, and S.K. Kulkarni Nitric oxide and major depression Nitric Oxide 24 2011 125 131
11. R.S. Duman, and L.M. Monteggia A neurotrophic model for stress-related mood disorders Biol Psychiatry 59 2006 1116 1127
12. L. Eroʇlu, and B. Caʇalayan Anxiolytic and antidepressant properties of methylene blue in animal models Pharmacol Res 36 1997 381 385
13. O. Fattal, K. Budur, A.J. Vaughan, and K. Franco Review of the literature on major mental disorders in adult patients with mitochondrial diseases Psychosomatics 47 2006 1 7
14. S.A. Gorman, A.L. Bell, J. Griffiths, D. Roberts, and S.B. Brown The synthesis and properties of unsymmetrical 3,7-diaminophenothiazin-5-ium iodide salts: potential photosensitisers for photodynamic therapy Dyes Pigments 71 2006 153 160
15. F.X. Guix, I. Uribesalgo, M. Coma, and F.J. Muñoz The physiology and pathophysiology of nitric oxide in the brain Prog Neurobiol 76 2005 126 152
16. A.J. Harkin, K.H. Bruce, B. Craft, and I.A. Paul Nitric oxide synthase inhibitors have antidepressant-like properties in mice. 1. Acute treatments are active in the forced swim test Eur J Pharmacol 372 1999 207 213
17. J.E. Harris, and A. Peters Experiments on vital staining with methylene blue Q J Microsc Sci 94 1953 113 124
18. B.H. Harvey Affective disorders and nitric oxide: a role in pathways to relapse refractoriness? Hum Psychopharmacol 11 1996 309 319
19. B.H. Harvey Is major depressive disorder a metabolic encephalopathy? Hum Psychopharmacol 23 2008 371 384
20. B.H. Harvey, I. Duvenhage, F. Viljoen, N. Scheepers, S.F. Malan, and G. Wegener Role of monoamine oxidase, nitric oxide synthase and regional brain monoamines in the antidepressant-like effects of methylene blue and selected structural analogues Biochem Pharmacol 80 2010 1580 1591
21. F. Hubálek, C. Binda, A. Khalil, M. Li, A. Mattevi, and N. Castagnoli Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors J Biol Chem 280 2005 15761 15766
22. M.J. Kelner, R. Bagnell, B. Hale, and N.M. Alexander Methylene blue competes with paraquat for reduction by flavo-enzymes resulting in decreased superoxide production in the presence of heme proteins Arch Biochem Biophys 262 1988 422 426
23. E.H. Kerns, and L. Di Drug-like properties: concepts, structure design, and methods: from ADME to toxicity optimization 1st ed. 2008 Academic Press Burlington
24. R.C. Kessler, P. Berglund, O. Demler, R. Jin, K.R. Merikangas, and E.E. Walters Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication Arch Gen Psychiatry 62 2005 593 602
25. R.C. Kessler, T.C. Wai, O. Demler, and E.E. Walters Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication Arch Gen Psychiatry 62 2005 617 627
26. S. Korff, D.J. Stein, and B.H. Harvey Stereotypic behaviour in the deer mouse: pharmacological validation and relevance for obsessive compulsive disorder Prog Neuropsychopharmacol Biol Psychiatry 32 2008 348 355
27. V. Krishnan, and E.J. Nestler The molecular neurobiology of depression Nature 455 2008 894 902
28. S.K. Kulkarni, and A. Dhir Effects of various classes of antidepressants in behavioral paradigms of despair Prog Neuropsychopharmacol Biol Psychiatry 31 2007 1248 1254
29. A. Küpfer, C. Aeschlimann, B. Wermuth, and T. Cerny Prophylaxis and reversal of ifosfamide encephalopathy with methylene blue Lancet 343 1994 763 764
30. A.L. Lin, E. Poteet, F. Du, R.C. Gourav, R. Liu, and Y. Wen Methylene blue as a cerebral metabolic and hemodynamic enhancer PLoS One 7 2012 e46585
31. Y.T. Lu, C. Arai, J.F. Ge, W.S. Ren, M. Kaiser, and S. Wittlin Synthesis and in vitro antiprotozoal activities of water-soluble, inexpensive phenothiazinium chlorides Dyes Pigments 89 2011 44 48
32. C.T. Lum, and S.M. Stahl Opportunities for reversible inhibitors of monoamine oxidase-A (RIMAs) in the treatment of depression CNS Spectr 17 2012 107 120
33. D. Luo, S. Das, and S.R. Vincent Effects of methylene blue and LY83583 on neuronal nitric oxide synthase and NADPH-diaphorase Eur J Pharmacol 290 1995 247 251
34. H.K. Manji, J.A. Quiroz, J. Sporn, J.L. Payne, K. Denicoff, and N.A. Gray Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression Biol Psychiatry 53 2003 707 742
35. P.K. Moore, and R.L. Handy Selective inhibitors of neuronal nitric oxide synthase-is no NOS really good NOS for the nervous system? Trends Pharmacol Sci 18 1997 204 211
36. T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J Immunol Methods 65 1983 55 63
37. K.M. Naseem The role of nitric oxide in cardiovascular diseases Mol Aspects Med 26 2005 33 65
38. G.J. Naylor, B. Martin, S.E. Hopwood, and Y. Watson A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis Biol Psychiatry 21 1986 915 920
39. G.J. Naylor, A.H. Smith, and P. Conelly A controlled trial of methylene blue in severe depressive illness Biol Psychiatry 22 1987 657 659
40. E.J. Nestler, M. Barrot, R.J. DiLeone, A.J. Eisch, S.J. Gold, and L.M. Monteggia Neurobiology of depression Neuron 34 2002 13 25
41. M. Oz, D.E. Lorke, and G.A. Petroianu Methylene blue and Alzheimer's disease Biochem Pharmacol 78 2009 927 932
42. M. Oz, D. Isaev, D.E. Lorke, M. Hasan, G. Petroianu, and T.S. Shippenberg Methylene blue inhibits function of the 5-HT transporter Br J Pharmacol 166 2012 168 176
43. C.U. Pae, J.A. Bodkin, K.B. Portland, M.E. Thase, and A.A. Patkar Safety of selegiline transdermal system in clinical practice: analysis of adverse events from postmarketing exposures J Clin Psychiatry 73 2012 661 668
44. A. Petzer, B.H. Harvey, G. Wegener, and J.P. Petzer Azure B, a metabolite of methylene blue, is a high-potency, reversible inhibitor of monoamine oxidase Toxicol Appl Pharmacol 258 2012 403 409
45. A. Petzer, A. Pienaar, and J.P. Petzer The inhibition of monoamine oxidase by esomeprazole Drug Res (Stuttg) 63 2013 462 467
46. R.D. Porsolt, G. Anton, N. Blavet, and M. Jalfre Behavioural despair in rats: a new model sensitive to antidepressant treatments Eur J Pharmacol 47 1978 379 391
47. R.D. Porsolt, G. Brossard, C. Hautbois, and S. Roux Models of affective illness: forced swimming and tail suspension tests in rodents S.J. Enna, M. Williams, J.F. Barret, J.W. Ferkany, T. Kenakin, R.D. Porsolt, Current protocols in pharmacology 1st ed. 2000 Wiley New York 581 589
48. J.C. Provost, C. Funck-Brentano, V. Rovei, J. D'Estanque, D. Ego, and P. Jaillon Pharmacokinetic and pharmacodynamic interaction between toloxatone, a new reversible monoamine oxidase-A inhibitor, and oral tyramine in healthy subjects Clin Pharmacol Ther 52 1992 384 393
49. R.R. Ramsay, C. Dunford, and P.K. Gillman Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction Br J Pharmacol 152 2007 946 951
50. P.D. Riha, A.K. Bruchey, D.J. Echevarria, and F. Gonzalez-Lima Memory facilitation by methylene blue: dose-dependent effect on behaviour and brain oxygen consumption Eur J Pharmacol 511 2005 151 158
51. C. Rivier Role of gaseous neurotransmitters in the hypothalamic-pituitary-adrenal axis Ann N Y Acad Sci 933 2001 254 264
52. S.C. Salaris, C.F. Babbs, and W.D. Voorhees Methylene blue as an inhibitor of superoxide generation by xanthine oxidase. A potential new drug for the attenuation of ischemia/reperfusion injury Biochem Pharmacol 42 1991 499 506
53. N. Sartorius, T.C. Baghai, D.S. Baldwin, B. Barrett, U. Brand, and W. Fleischhacker Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence Int J Neuropsychopharmacol 10 Suppl. 1 2007 1 207
54. T.L. Schwartz A neuroscientific update on monoamine oxidase and its inhibitors CNS Spectr 18 Suppl. 1 2013 25 32
55. S.Y. Son, J. Ma, Y. Kondou, M. Yoshimura, E. Yamashita, and T. Tsukihara Structure of human monoamine oxidase A at 2.2-Å resolution: the control of opening the entry for substrates/inhibitors Proc Natl Acad Sci U S A 105 2008 5739 5744
56. S.C. Stanford, B.J. Stanford, and P.K. Gillman Risk of severe serotonin toxicity following co-administration of methylene blue and serotonin reuptake inhibitors: an update on a case report of post-operative delirium J Psychopharmacol 24 2010 1433 1438
57. E. Suzuki, G. Yagi, T. Nakaki, S. Kanba, and M. Asai Elevated plasma nitrate levels in depressive states J Affect Disord 63 2001 221 224
58. T.M. Visarius, J.W. Stuki, and B.H. Lauterburg Stimulation of respiration by methylene blue in rat liver mitochondria FEBS Lett 412 1997 157 160
59. V. Volke, G. Wegener, E. Vasar, and R. Rosenberg Methylene blue inhibits hippocampal nitric oxide synthase activity in vivo Brain Res 826 1999 303 305
60. M. Wainwright, and R.M. Giddens Phenothiazinium photosensitisers: choices in synthesis and application Dyes Pigments 57 2003 245 257
61. A. Warth, B. Goeppert, C. Bopp, P. Schirmacher, C. Flechtenmacher, and J. Burhenne Turquoise to dark green organs at autopsy Virchows Arch 454 2009 341 344
62. G. Wegener, V. Volke, B.H. Harvey, and R. Rosenberg Local, but not systemic, administration of serotonergic antidepressants decreases hippocampal nitric oxide synthase activity Brain Res 959 2003 128 134
63. G. Wegener, B.H. Harvey, B. Bonefeld, H.K. Müller, V. Volke, and D.H. Overstreet Increased stress-evoked nitric oxide signalling in the Flinders sensitive line (FSL) rat: a genetic animal model of depression Int J Neuropsychopharmacol 13 2010 461 473
64. Wischik, C.M., Rickard, J.E., Harrington, C.R., Horsley, D., Storey, J.M.D., Marshall, C., Sinclair, J.P., Wan Tan, H., 2006. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride. Patent: US 2006/0287523 A1.
65. M.B. Youdim, and M. Weinstock Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation Neurotoxicology 25 2004 243 250